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Abstract
OBJECTIVES: Because of the limited availability of pulmonary homografts (PH),
porcine stentless xenografts (SX) have been proposed as an alternative for
pulmonary valve replacement in the Ross operation. However, it is unknown
whether they have similar good long-term durability. Therefore, we compared
mid- to long-term outcomes between those two right ventricular outflow tract
(RVOT) substitutes. METHODS: In 288 adults (>18 years) undergoing a Ross
operation between 1991 and 2012, Freestyle(®) SX was used in 18 patients and
a cryopreserved PH was used in 270 for RVOT reconstruction. Only patients with
follow-up >2 years were included. According to the operative period, gender and
age, 37 patients with PH could be matched with 17 SX patients. Clinical and
echocardiographic follow-up were obtained. In a subset of patients (SX, n = 11
and PH, n = 25), a cardiac computed tomographic (CT) scan was performed to
analyse graft calcification. RESULTS: The mean follow-up period was 8.2 ± 4.0...
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Abstract
OBJECTIVES: Because of the limited availability of pulmonary homografts (PH), porcine stentless xenografts (SX) have been proposed as
an alternative for pulmonary valve replacement in the Ross operation. However, it is unknown whether they have similar good
long-term durability. Therefore, we compared mid- to long-term outcomes between those two right ventricular outﬂow tract (RVOT)
substitutes.
METHODS: In 288 adults (>18 years) undergoing a Ross operation between 1991 and 2012, Freestyle® SX was used in 18 patients and a
cryopreserved PH was used in 270 for RVOT reconstruction. Only patients with follow-up >2 years were included. According to the op-
erative period, gender and age, 37 patients with PH could be matched with 17 SX patients. Clinical and echocardiographic follow-up
were obtained. In a subset of patients (SX, n = 11 and PH, n = 25), a cardiac computed tomographic (CT) scan was performed to analyse
graft calciﬁcation.
RESULTS: The mean follow-up period was 8.2 ± 4.0 (range 2–14.6 years). During this period, 3 patients died from cancer, 2 in the SX
group and 1 in the PH group (P = 0.15). No patient needed RVOT reoperation. At follow-up, RVOT peak gradient was 21 ± 5.9 mmHg in
the SX and 16.3 ± 8.7 in the PH groups (P = 0.07). Peak gradient >40 mmHg was observed in only 1 patient in the PH group. Mean
RVOT regurgitation was 0.1 ± 0.4 in the SX group and 0.8 ± 0.6 in the PH group (P = 0.008). CT scan analyses showed progressive calciﬁ-
cation mainly of the graft wall, while the valve remained relatively free of calcium. Patients with the SX presented signiﬁcantly higher
calcium scores than those with PH (P = 0.01).
CONCLUSIONS: In adult patients having the Ross operation, calcic degeneration is observed in both the PH and the SX used as pul-
monary substitutes. Calciﬁcation progresses more rapidly in the SX compared with the PH. In both grafts, calciﬁcations affect mainly
the wall, while the valve remains relatively free of calcium. As a consequence, both grafts show good and similar haemodynamic out-
comes at mid- to long-term follow-up. The Freestyle® SX can be considered as an acceptable alternative for RVOT reconstruction when
PH is not available.
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INTRODUCTION
In young adults with aortic valve dysfunction, the Ross operation
is an attractive alternative to prosthetic aortic valve replacement.
Indeed, it offers an excellent long-term survival, without the
need for life-long anticoagulation, with more physiological
haemodynamics and good durability of the pulmonary autograft
[1–3]. The cost of those beneﬁts is a more complex surgical pro-
cedure in comparison with prosthetic valve implantation, and
the need for the right ventricular outﬂow tract (RVOT)
reconstruction. The cryopreserved pulmonary homograft (PH) is
the most used substitute and is currently considered the gold
standard in this indication. It has shown a good durability with
95% freedom from reintervention in adults and between 80 and
90% in children [1, 4–6]. The main disadvantage of homografts is
their limited availability in all graft sizes. This has led surgeons
to use other valved grafts for RVOT reconstructions [7]. Stentless
xenografts (SX), originally developed to compete with aortic bio-
prostheses, have been suggested by several teams as an interesting
option for RVOT reconstruction, with encouraging preliminary results
[8–10]. Our group has used since 1998 the Freestyle® SX
(Medtronic, Inc., Minneapolis, MN, USA) in selected adult
patients undergoing Ross operations.
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The aim of this study was to review our experience with the
Freestyle® in this indication and to compare this graft with the
PH. The comparison of both substitutes was made on mid- to
long-term clinical and haemodynamic outcomes and on the
degree of calcic degeneration.
PATIENTS AND METHODS
Patients
Between 1991 and 2012, 288 adult patients underwent a Ross
operation in our institution. Surgery was performed by two
experienced surgeons (G.K. and J.R.). In 270 patients, the RVOT
was reconstructed with a cryopreserved PH from the European
Homograft Bank (EHB, International Association, Brussels,
Belgium). The use of the SX for RVOT reconstruction was intro-
duced in the year 1998 for adult patients in whom no appropri-
ate size of the PH was available, or in a few patients in whom
the decision to perform a Ross procedure was taken intraopera-
tively. A total of 18 SX were used during this period. Because
mid- to long-term outcomes were analysed in this study, we
included only patients with a follow-up >2-years (SX, n = 17 and
PH, n = 253).
The principal factors inﬂuencing the PH degeneration are:
young recipient age, young donor age, length of cryopreserva-
tion, homograft size and the duration since implantation [2, 6, 11].
To compare the results of SX and PH, we selected a subgroup of
PH patients who had characteristics similar to those of SX patients.
The selection criteria were based on patient-related factors
involved in graft degeneration: recipient age at implantation (±24
months) and duration since implantation (±12 months). For mor-
phometric reasons, gender was used as a third selection criterion.
For each SX patient, one or more PH patients meeting the criteria
were selected, knowing that a certain percentage would deny
undergoing the imaging studies proposed for the study. Following
these criteria, we were able to select a subgroup of 37 PH
patients. These 37 PH and the 17 SX patients represent the study
cohort. Homograft-related factors, like donor age and length of
cryopreservation, were not used for matching as obviously no cor-
respondence existed in the SX group. For the same reason, the
graft size was not used as selection criterion, because the labelled
size of the two grafts does not represent the same measures (PH
size = internal diameter and SX size = external diameter).
Patient characteristics and operative data were collected from
patient charts and operative notes. The institutional ethics com-
mittee approved the study protocol.
Operative techniques
The Ross procedure was performed in a relatively standard way.
The details of our technique were described in a previous work
[12]. The techniques of autograft implantation included ‘inclusion
cylinder’ and ‘freestanding root’. As mentioned in a previous
paragraph, PHs were the ﬁrst choice for RVOT reconstruction.
The largest size available at the homograft bank was generally
implanted. Both the proximal and distal anastomoses were per-
formed with running sutures of Prolene 4/0. A small piece of
Teﬂon felt was used only to tie the running suture on the RVOT.
Care was taken to avoid PH torsion and purse string effect at the
distal anastomosis. For SX implantation, the technique was
similar. The largest size available for the SX (27 and 29 mm) was
systematically used.
Follow-up
Clinical follow-up was conducted through either outpatient visits
or telephone follow-up by a research nurse. Information on sur-
vival status and valve-related complications, including thrombo-
embolism, haemorrhage, endocarditis, reoperation and cardio-
vascular symptoms, was obtained. The closing interval for the
study was between March and August 2012. Clinical follow-up
was 100% complete. Mean follow-up was 7.3 ± 3.5 (range 2–
14.5) years in the SX group and 8.6 ± 4.1 (range 2–14.6) years in
the PH group (P = 0.28). The distribution of patients regarding
the operative period was balanced: 28% (n = 15) had <5 years of
follow-up, 37% (n = 20) had 5–10 years of follow-up and 35%
(n = 19) had >10 years of follow-up.
Echocardiographic analysis
Transesophageal echocardiography was systematically performed
intraoperatively, and transthoracic echocardiography (TTE) was
obtained before discharge and at regular intervals during the
follow-up. For patients followed in another institution or having
no recent TTE, we asked them to perform this examination in
our institution. Echographic data were obtained with the com-
mercially available ultrasound systems: SONOS® 7500 and more
recently the iE33 xMATRIX® (Philips Healthcare, Cleveland, OH,
USA) with a second harmonic broadband, wide angle matrix
array transducer (3.5/1.7 MHz).
All patients underwent a comprehensive examination, includ-
ing M-mode, two-dimensional echocardiography, as well as con-
ventional and colour Doppler examinations from parasternal and
apical views. Transvalvular pulmonary gradients were calculated
from the continuous Doppler waves, using the Bernoulli equa-
tion. The degree of regurgitation was evaluated by colour-ﬂow
Doppler mapping and staged as absent, mild, moderate or
severe. The annulus size of the pulmonary graft was measured
on a long-axis view at the level of the pulmonary valve insertion.
The right ventricle (RV) assessment was performed through the
apical four-chamber view: basal, mid-cavity and longitudinal dia-
meters were measured. The RV function was estimated by meas-
uring the fractional area change.
Discharge and last follow-up TTE were blinded reviewed by
one cardiologist experimented in echocardiography ( J.M.). TTE
was available for analysis in 14 (82%) patients in the SX group (2
deaths and 1 patient denied to undergo TTE) and in 36 (97%) in
the PH group (1 death). The mean TTE follow-up was 7.1 ± 3.8
years in the SX group and 8.1 ± 4.2 years in the PH group
(P = 0.47).
Computed tomographic scanner acquisition
and analysis
A computed tomographic (CT) scan was proposed to all patients
included in the study. A CT scan was performed using a
Brilliance® iCT256 scanner (Philips Healthcare). Serial images were
prescribed over the heart and acquired using a prospectively
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electro-cardiographically gated acquisition. Tube current was 900
mA and voltage, 100 kV. Images were acquired using 0.5-mm
section thickness and reconstructed to 0.9-mm thickness. All scans
were blinded reviewed on a dedicated workstation using a dedi-
cated software (HeartBeatCS®, Philips Medical Systems, Cleveland,
OH, USA) by one experienced operator (B.G.). A degree of pul-
monary valve and tube calciﬁcation was quantiﬁed both using the
Agatston [13] Score and Volume Score. CT scans were available in
11 (65%) patients in the SX group (2 deaths and 4 denied to
undergo a CT scan) and in 25 (68%) in the PH group (1 death and
11 denied to undergo a CT scan). In this subgroup of patients, the
mean follow-up was 7.8 ± 3.9 years in the SX group and 8.8 ± 4.1
years in the PH group (P = 0.47).
Statistical analysis
Categorical variables were reported as absolute numbers and
percentages and compared with Pearson’s χ2 test. Continuous
variables were expressed as mean ± standard deviation or median
(inter-quartile range) if not normally distributed. The normal distri-
bution of continuous variables was tested with the Kolmogorov–
Smirnov test. Variables of normal distribution were compared by
two-tailed Student’s t-test, otherwise the non-parametric Mann–
Whitney U-test was used. Statistical signiﬁcance was considered
for a P-value ≤0.05. For correlation studies, correlation coefﬁcients
were calculated between datasets for the linear, cubic, polynomial,
exponential and logarithmic models. The model with the highest
correlation coefﬁcient was retained, namely the exponential
model for Fig. 4 and the linear model for Fig. 5. For estimation of
the regression lines, the software used the method of least
squares, and the best-ﬁt curve for the model chosen is the one
with the minimal sum of the deviations squared from the set of
data. The strength of the correlation was estimated by Spearman’s
Rho test and was considered as weak for a Rho <0.4, moderate
between 0.4 and 0.7 and strong >0.7. The statistical analysis was
performed with SPSS v15.0 (IBM Inc., Chicago, IL, USA).
RESULTS
Patient’s demographic and preoperative characteristics are listed
in Table 1. No statistically signiﬁcant differences were found
between the two groups in terms of age, gender, body surface
area, symptomatology, type of aortic valve dysfunction and left
ventricular ejection fraction.
Operative results
In the SX group, the ﬁrst two patients received a 27-mm valve,
and then a 29-mm valve was implanted in the 15 following
patients. In the PH group, the mean size of the PH implanted
was 25 ± 1.5 (range 23–28) mm. Techniques of autograft implant-
ation, associated procedures and operative times were similar in
both groups (Table 2). There was no hospital mortality. Major
postoperative complications are listed in Table 2.
Long-term clinical outcomes
During the follow-up period, 3 patients died, all from cancer
(SX, n = 2 and PH, n = 1; P = 0.15). No patient needed RVOT reinter-
vention for SX or PH dysfunction. At last follow-up, all patients
were in NYHA Class I or II, with no difference between the two
groups (SX, Class I = 10, Class II = 5 and PH, Class I = 27, Class II = 9;
P = 0.79).
Table 1: Patients preoperative characteristics
Variables Stentless xenografts (17) Pulmonary homografts (37) P-value
Age (years ± SD, [range]) 48.6 ± 8.2 [36–57] 46.4 ± 5.8 [34–55] 0.28
Sex (males) 13 (76.5%) 31 (83.8%) 0.52
Body surface area (m²) 2.0 ± 0.2 2.0 ± 0.2 0.47
Previous surgery 2 (11.8%) 3 (8.1%) 0.66
Clinical status
New York Heart Association I 2 (11.8%) 11 (29.7%)
0.30New York Heart Association II 10 (58.8%) 15 (40.5%)
New York Heart Association III 5 (29.4%) 11 (29.7%)
Aortic valve pathology
Aortic stenosis 2 (11.8%) 12 (32.4%)
0.17Aortic regurgitation 7 (41.2%) 8 (21.6%)
Mixed (aortic stenosis + aortic regurgitation) 8 (47%) 17 (46%)
Aortic valve disease aetiology
Congenital 11 (64.7%) 27 (73%)
0.97
Tricuspid degenerative 3 (17.6%) 4 (10.8%)
Rheumatic 1 (5.9%) 2 (5.4%)
Endocarditis 1 (5.9%) 2 (5.4%)
Valve prosthesis failure 1 (5.9%) 2 (5.4%)
Left ventricular function
Left ventricle ejection fraction >50% 14 (82.3%) 34 (91.9%)
0.58Left ventricle ejection fraction 30–50% 2 (11.8%) 2 (5.4%)
Left ventricle ejection fraction <30% 1 (5.9%) 1 (2.7%)
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Echocardiographic results
The discharge and follow-up TTE results are presented in
Table 3. Despite a relative difference in the mean labelled size of
SX and PH implanted, the annulus diameter and peak gradient
were similar at discharge between the two types of pulmonary
substitutes. From discharge to follow-up, both groups showed an
increase in peak gradient; however, the gradient remained, in
the majority of patients, in an acceptable clinical range. Peak
gradient >40 mmHg was observed in only 1 patient from the PH
group (P = 0.49). The peak gradient increased slightly more in
the SX compared with the PH group, but the difference between
the two groups was not statistically signiﬁcant (Table 3 and
Fig. 1). At follow-up, RVOT regurgitation was nil in 79% and
Grade 1 in 21% in the SX group; and in the PH group, regurgita-
tion was nil in 31%, Grade 1 in 58% and Grade 2 in 11%
(P = 0.008).
Finally, follow-up TTE’s showed similar RV dimensions
between the two groups. Basal diameter was 44 ± 7 in SX vs
45 ± 7 mm in PH (P = 0.6), mid-cavity diameter was 33 ± 6 in SX
vs 34 ± 7 mm in PH (P = 0.85) and longitudinal diameter was
76 ± 4 in SX vs 79 ± 7 mm in PH (P = 0.3). The RV fractional area
change was also similar between groups (SX, 51 ± 7% and PH,
48 ± 6%; P = 0.15).
Computed tomographic scanner results
The CT scan analyses showed that calciﬁcation affects essentially
the wall of the grafts, while the valves remain relatively free of
calcium (Fig. 2). Overall, patients in the SX group presented sig-
niﬁcantly higher calcium scores compared with those in the PH
group (Table 3). The difference between the groups is observed
already in the mid-term follow-up interval and increases in the
long-term follow-up intervals (Fig. 3). Correlation analyses showed
that graft calciﬁcation increases exponentially with time in both
grafts, with a more rapid progression in the SX group (Fig. 4).
Between the calcium score and peak gradient, a linear correlation
was found in each group (Fig. 5). The near-to-horizontal slopes of
the correlation lines, related to the a coefﬁcient in the line equa-
tions (SX, a = 0.001 and PH, a = 0.002), are consistent with the rela-
tively low degree of calciﬁcation observed in the valve cusps
(Fig. 2).
DISCUSSION
In his initial experience with the Ross procedure during the
1970s, Donald Ross had used aortic homografts and other au-
tologous tissues to reconstruct the RVOT [7]. One decade later,
PHs were introduced, and their superior results compared with
aortic homografts made them the gold standard for this indica-
tion [14]. However, the shortage of suitable homografts in
Table 3: Postoperative echocardiographic and CT scan results
Discharge TTE Follow-up TTE CT scan P-valueb
Annulus
diameter
(mm)
Pulmonary
regurgitation
Peak
gradient
(mmHg)
Pulmonary
regurgitation
Peak
gradient
(mmHg)
Peak
gradient
increase
(mmHg)
Calcium volume
(mm3)a
Agatston Scorea
Stentless
xenografts
21.6 ± 1.5 0 11.9 ± 4.5 0.1 ± 0.4 21 ± 5.9 9.5 ± 5.5 2782 [671–5666] 1213 [829–7286] 0.17; <0.001
Pulmonary
homografts
22.3 ± 1.6 0.2 ± 0.2 9.4 ± 4.9 0.8 ± 0.6 16.3 ± 8.7 5.4 ± 8.8 351 [211–936] 398 [196–1322] 0.006; 0.007
P-value 0.26 0.28 0.14 0.008 0.07 0.16 0.006 0.015 –
aMedian [interquartile range].
bCompare pulmonary regurgitation and peak gradients between discharge and follow-up TTE within the SX and PH groups.
CT: computed tomography; TTE: transthoracic echocardiography.
Table 2: Operative data and postoperative results
Variables Stentless
xenografts
(17)
Pulmonary
homografts
(37)
P-value
CPB time (min) 152 ± 26 154 ± 27 0.79
Cross-clamping time (min) 127 ± 19 127 ± 17 0.98
Autograft implantation
Inclusion cylinder 6 (35.3%) 14 (37.8%) 0.86
Free standing root 11 (64.7%) 23 (62.2%) –
Pulmonary substitute size
(mm)a
27 (n = 2) 25 ± 1.5 –
29 (n = 15) – –
Concomitant procedures
AAR with Dacron graft 4 (23.5%) 7 (18.9%) 0.98
Mitral valve repair 1 (5.9%) 4 (10.8%) 0.94
CABG 1 (5.9%) 2 (5.4%) 0.57
Subaortic membrane
resection
1 (5.9%) 0 (0%) 0.69
Postoperative complication
Mortality 0 0 –
Reoperation for bleeding 1 (5.9%) 1 (2.7%) 0.84
Pericardial effusion 0 (0%) 4 (10.8%) 0.39
Myocardial infarction 0 (0%) 1 (2.7%) 0.69
Permanent pace maker
implantation
1 (5.9%) 0 (0%) 0.69
AAR: ascending aortic replacement; CABG: coronary artery bypass
graft; CPB: cardiopulmonary bypass.
aIn the SX group: all patients received a 29-mm (larger available size)
size, except 2 who received 27 mm; In the PH group: the number
represents the mean inner diameter of the inflow given by the tissue
bank.
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paediatric patients, the lack of human tissue availability at some
periods or in some countries and the PH failure due to structural
degeneration have led to the consideration of other alternatives
for RVOT reconstruction [7]. Accordingly, SXs appeared attractive
because of their availability and their anticalciﬁcation treatments.
In this study, we analysed the mid- to long-term results of the
Freestyle® SX used in adult patients having the Ross operation.
We showed that RVOT can be safely reconstructed with the SX.
In comparison with PH, the SX showed similar clinical outcomes
with no need for reintervention after a mean follow-up of 8
years. Over time, transvalvular gradients increased in both grafts,
but remained in acceptable clinical ranges in most patients. In
comparison with the PH, the SX presented a slightly greater in-
crease in transvalvular gradients, but a lower increase in regurgi-
tation. Calcic degeneration occurred in both grafts and involved
predominantly the wall of the graft, leaving the cusps relatively
free of calcium. Calciﬁcations progressed more rapidly and se-
verely in the wall of the SX than in the PH.
Like other bioprostheses, the PH is subject to structural degen-
eration due to immune reactions from the host [15]. The PH dys-
function, mainly stenosis, resulting from that degeneration
occurs more frequently and earlier after implantation in children
in comparison with adults, in patients receiving smaller PH, in
PH from younger donor age and in PH with shorter duration of
cryopreservation [2, 6, 11]. Following several large series, after
one decade, the freedom from PH reintervention ranges from
93 to 100% in adults and from 80 to 90% in children [1, 4–6, 12,
16]. Regarding the other RVOT substitutes, aortic homografts in
the pulmonary position did worse in comparison with PH with
freedom from reintervention of 70% after 5 years only in a pre-
dominantly paediatric population [14]. The bovine jugular vein
(Contegra®, Medtronic, Inc.), developed essentially to provide
small conduits for children, showed freedom from reintervention
at 10 years ranging from 70 to 90% depending on the conduit
size [17, 18]. In comparison with PH, bovine jugular veins seemed
to do as well or even better, in children <2 years [17–19].
Regarding the use of SXs in the Ross, few data are available in
the literature. The studies include small series (<20 patients) that
show all good short-term results in adults, or in children, with
no need for reintervention after a mean follow-up of 3 years [8–
10]. This study is the ﬁrst to bring mid- to long-term follow-up
data with clinical, haemodynamic and calcic degeneration ana-
lysis of the SX compared with the PH. While CT scan analyses
showed more severe calciﬁcation in the SX, echocardiographic
analyses showed relatively similar deterioration of valve function
over time in both groups. Relevant valve regurgitation, which isFigure 1: Box plot illustrating the evolution of the peak gradient along inthree different periods of follow-up.
Figure 2: (A) Volume intensity projection (VIP) image of a calciﬁed PH implanted 8 years ago; (B) volume rendering image of the calciﬁed PH (anterior view);
(C) volume rendering image of the calciﬁed PH (inferior view); (D) VIP image of a SX xenograft implanted 12 years ago; (E) volume rendering image of the calci-
ﬁed SX (anterior view) and (F) volume rendering image of the calciﬁed SX (inferior view).
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a typical mode of failure of the SX in the aortic position, was not
observed in this study, probably because the low pressure in the
right heart does not have the strength to tear the leaﬂets
weakened by structural degeneration like it does in the left
heart [20].
We found that calcic degeneration increased with time, essen-
tially on the wall of the grafts and more rapidly in the SX group.
These ﬁndings explain the relatively preserved valve function in
both the groups and conﬁrm in the human the observations
made by Flameng et al. [21] in an experimental study. In that
study, the authors compared structural degeneration of aortic
homografts, PHs and different types of SXs (porcine and bovine)
implanted in the pulmonary position of adolescent sheep. They
found severe calciﬁcations in the wall portion of the porcine
xenografts irrespective of the antimineralization treatment. Aortic
homografts walls also showed more calcium than PHs. Leaﬂet
calciﬁcation or pannus was mild and similar between aortic, PHs
and porcine xenografts. In this study, the bovine jugular vein
showed wall calciﬁcations, but leaﬂets were free of calciﬁcation
or pannus. Finally, the bovine pericardial conduit (Pericarbon®,
Sorin Group, Milan, Italy) showed no calciﬁcations, but extensive
pannus overgrowth with leaﬂet retraction. In a randomized study
comparing aortic homografts and Freestyle® in the aortic pos-
ition, El-Hamamsy et al. showed at long-term greater calciﬁca-
tions of aortic homografts in the long term [22]. However, their
data and ours suggest similar calciﬁcation rates of the Freestyle®
either on the aortic or the pulmonary position.
The Freestyle® SX is ﬁxed with glutaraldehyde at zero pressure
on the cusps and exposed to alpha-amino oleic acid as antimi-
neralization treatment. PHs are exposed to antibiotics and then
cryopreserved without chemical ﬁxation. In both the SX and PH,
structural degeneration is related to a certain degree of immune
and inﬂammatory reaction [15, 20]. It has been demonstrated
that the mineralization process in bioprosthetic valves is initiated
within the nonviable connective tissue cells devitalized, but not
removed, by glutaraldehyde or cryopreservation pretreatments
[23]. For this reason, human decellularized pulmonary valves (e.g.
Synergraft SG®, CryoLife, Inc., Kenesaw, GA, USA) have been
developed to offer the potential for better performances due to
the reduced degree of rejection [24]. These new grafts showed
encouraging short- to mid-term results; [25] however, long-term
data are necessary to conﬁrm whether they offer better durabil-
ity compared with non-decellularized homografts.
Limitations of the study
One limitation of this cohort study is that patients were not ran-
domized for the choice of the pulmonary valve substitute. The
comparison between the groups was based on a selection of PH
patients meeting some of the criteria reported to inﬂuence bio-
prosthesis degeneration. As such, other patient-related factors or
factors like duration of cryopreservation, donor age and graft
size can have inﬂuenced the results obtained in this study.
However, despite the graft size not being used for matching,
interestingly, both groups showed a similar mean internal diam-
eter of the graft after implantation.
Despite the long period of recruitment (1998–2010), the tech-
nique of implantation and preparation of the graft remained the
same over this period. Variability related to the measurement
methods, or materials, was minimized by reanalysing the source
data (echographic images) by one-blinded experimented oper-
ator and by performing new follow-up evaluations (echo and CT
scan).
Figure 5: Linear correlation between peak gradients and Agatston Calcium
Scores in pulmonary homografts (line equation: y = 0.002x + 13.1) and stent-
less xenografts (line equation: y = 0.001x + 16.6).
Figure 4: Exponential correlation between Agatston Calcium Scores and
follow-up in pulmonary homografts and stentless xenografts.
Figure 3: Box plot illustrating the evolution of the Agatston Calcium Score
along in three different periods of follow-up.
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The statistical power of the study was evaluated with com-
promise post hoc power analyses using GPower3 Software
(Universitat Kiel, Germany). With a signiﬁcance set at 0.05 and
an error probability ratio at 1, the analysis revealed that, for the
sample size and effect size, the power was 0.82 to detect differ-
ences in gradients and 0.89 to detect differences in calcium
scores. In clinical studies, a power >0.8 is generally
recommended.
CONCLUSION
In adult patients having the Ross operation, calcic degeneration
is observed in both PHs and Freestyle® SXs used as pulmonary
substitutes. Calciﬁcation progresses exponentially, with a more
rapid increase in SXs compared with PHs. In both grafts, calciﬁ-
cations affect mainly the wall, while the valve remains relatively
free of calcium. As a consequence, both grafts showed good and
similar haemodynamic outcomes at mid- to long-term follow-
up. Considering these data, the Freestyle® SX can be considered
as an acceptable alternative for RVOT reconstruction in the Ross
procedure when a PH is not available. Further analyses are man-
datory, particularly to determine whether the greater degree of
calcic degeneration observed in SX will cause severe dysfunction
in the longer term.
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APPENDIX. CONFERENCE DISCUSSION
Dr W. Hargrove (Philadelphia, PA, USA): First, I’d say this is an observational
study. I’m a little skeptical about making statistical analysis when you have so
few patients. I know you did a type of propensity matching, but with 17 in
one group and 37 in the other, I’m not sure; again, I’m not a statistician, but
I’m not sure about that other than observation.
I have three questions. The ﬁrst question is: What, if any, anatomical modi-
ﬁcations of the xenograft did you need to make to place it into the right ven-
tricular outﬂow tract to ﬁt better? Two, based on your analysis of the calcium
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scores and the CT scans, do you think possibly the cell-depleted xenografts
may become the new Holy Grail? And ﬁnally, if you needed a Ross procedure
next week, what would you tell the surgeon that you wanted to have placed
in your right ventricular outﬂow tract?
Dr Hechadi: Excuse me, I didn’t understand the two last questions. Can
you repeat.
Dr Hargrove: The ﬁrst, based on your analysis of the calcium score, you
mentioned it somewhat in your discussion about the cell-depleted xenografts
perhaps calcifying less, do you think this will be a better alternative than the
standard xenograft? And the ﬁnal is: If you needed a Ross procedure yourself,
what would you tell the surgeon you wanted placed in your right ventricular
outﬂow tract?
Dr Hechadi: In our centre, the institutional attitude is to use pulmonary
homografts systematically for Ross procedures. So stentless xenografts were
placed only when the Ross procedure was not initially planned or in the
emergency cases. That’s why we have few patients; we systematically use pul-
monary homografts. So it’s clear here that stentless xenografts calcify more,
and we propose it just as an alternative. Pulmonary homografts remain the
gold standard for this indication and the stentless xenografts are proposed
only if the pulmonary homografts are not available or not available in suitable
sizes.
Dr L. De Kerchove (Brussels, Belgium): I’m one of the coauthors of this
study. If I can add some information to the question asked by my colleague
from Philadelphia.
Concerning your ﬁrst question, do we trim the xenograft for implantation?
No, we don’t trim it. As it is, it ﬁts relatively well to reconstruct the RVOT. The
decellularized homograft is one of the options for the future. We actually
have only short- and mid-term follow-up regarding the function of those
substitutes in the right ventricular outﬂow tract. We lack the long-term results,
so it’s difﬁcult to compare the clinical results with the cellularized homografts
that we actually used. Those give quite good results, especially in the adult
population.
So what is our actual approach for RVOT reconstruction? Dr. Hechadi told
you, homografts; we are quite happy with them and in Brussels, we have a
very nice homograft bank which provides us with a lot of very good homo-
grafts. And this is actually our ﬁrst choice. If a lack of homografts is the case
in your country, your institution, a xenograft is a substitute that can be used
with so far good clinical long-term results.
Dr H. Schaefers (Homburg/Saar, Germany): I would like to address the last
aspect. If I recall the data correctly, the mean gradient across the outﬂow tract
increased in an almost linear fashion. And in the group 10 to 15 years, which is
a relatively wide window, it was close to 30 mmHg. You brieﬂy mentioned the
results of the statistical test, which, because of the variability, did not show a
statistical signiﬁcance. On the other hand, I would think that after 10–15 years,
for an operation that should have a long durability, a mean gradient of
30 mmHg is deﬁnitely clinically relevant. Would you like to comment?
Dr Hechadi: I don’t think so, because the peak gradient of 30 mmHg is not
too high. The indication for reoperation for RVOT is a peak gradient of 70
mmHg. We were speaking here about peak gradients. We don’t speak about
mean gradients.
Dr S. Takamoto (Tokyo, Japan): In your slide, the peak pressure gradient
through the pulmonary xenograft is increased in the longer follow-up time. If
it is increased to a critical level, 50 mmHg, how do you treat the patient?
Dr Hechadi: In these patients, in the stentless group there was no reopera-
tion because the highest peak gradient we had in our series was about 36
mmHg. In the homograft group, we had some reoperations. In the others,
there was about 20% of reoperations because they had peak gradients >70
mmHg. But in the stentless group we didn’t have reoperations at all.
For reoperations, it was standard surgical re-replacement by a pulmonary
homograft. We didn’t use the Melody valve or anything like that.
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